For Alphabet’s Verily, O is for OneOncology. The two companies have partnered up to accelerate cancer clinical trials.
OneOncology, which brings together independent oncology practices, will integrate Verily’s SignalPath clinical trial management software into its member practices. The technology will allow the participating sites to improve their system infrastructure, streamline regulatory processes and enhance collaboration with sponsors. Financial details were not disclosed.
The goal of the partnership is to expand opportunities for research to community oncology centers, thereby increasing access and participation in cancer studies.
Verily was founded by Google parent company Alphabet to discover ways to use technology to improve health. The spinout was previously doing a lot of work in the medtech and health tech space, including the development of the Onduo virtual care app for Type 2 diabetes. But those efforts were slimmed down in January as the company narrowed its focus and cut 15% of staff.
Similar to the OneOncology partnership, Verily worked with the Crohn’s & Colitis Foundation last year to develop a registry of patients with inflammatory bowel disease to help spur more research.